Čájehuvvojit 1 - 5 oktiibuot 5 bohtosis ohcui Jonathan Torchia (16797709)', ohcanáigi: 0,01s Aiddostahte ozu
  1. 1
    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Dahkki Stephanie Lheureux (16797697)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Dahkki Stephanie Lheureux (16797697)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Dahkki Stephanie Lheureux (16797697)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Dahkki Stephanie Lheureux (16797697)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... Dahkki Stephanie Lheureux (16797697)

    Almmustuhtton 2025
    Eará dahkkit:
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: